Bicara Therapeutics initiated with a Buy at Rodman & Renshaw
The Fly

Bicara Therapeutics initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw initiated coverage of Bicara Therapeutics (BCAX) with a Buy rating and $48 price target The firm says the opportunity arising from the dual-targeting mechanism of ficerafusp and a higher probability for success in PD-L1-positive head and neck cancers provide for the majority of its valuation for the shares.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App